Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced that new data from the Phase 3 DAYBREAK trial showed sustained decreased rates of brain volume loss in patients with relapsing forms of multiple sclerosis treated with Zeposia (Ozanimod) during the open-label extension.
September 18, 2024 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Phase 3 DAYBREAK trial results for Zeposia indicate sustained benefits in reducing brain volume loss in MS patients, potentially boosting the drug's market appeal.
The positive results from the Phase 3 DAYBREAK trial for Zeposia could enhance its market position and lead to increased sales, positively impacting Bristol Myers Squibb's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90